- Selank derives from the immune peptide tuftsin and skews toward anxiolytic GABAergic mechanisms, while Semax derives from the ACTH(4-10) fragment and skews toward neurotrophic and cognitive pathways.
- Both are early-human research materials with limited human data, and across the indexed literature neither reported outcomes by sex despite many studies including female subjects.
- The clearest thing Selank and Semax share is their female-evidence gap: no cycle, hormonal, pregnancy, or menopausal data exists for either.
Selank and Semax travel together. They were both developed in Russia, both are short synthetic peptides, and both show up in the same nootropic and calm-and-focus conversations, often presented as a pair or even stacked. But they come from different parent molecules and were characterized against different pathways, so treating them as interchangeable misses the point. This comparison lays out how their studied mechanisms and evidence differ, and what neither has answered for women.
Different origins, different pathway emphasis
Selank is a synthetic heptapeptide analog of tuftsin, an immunomodulatory peptide, and its studied mechanisms lean anxiolytic: GABAergic signaling, BDNF expression, monoamine balance, and enkephalin-degradation pathways. Semax is a synthetic analogue of the ACTH fragment 4-10, and its studied mechanisms lean neurotrophic and cognitive: BDNF and nerve-growth-factor expression alongside dopaminergic and serotonergic signaling, with additional work on cerebral blood flow and neuroinflammation. Selank engages a broad set of neuropeptide pathways; Semax is characterized against a comparatively specific mechanism, which makes it easier to study in isolation.
Side by side
| Selank | Semax | |
|---|---|---|
| Parent molecule | Tuftsin (immunomodulatory peptide) analog | ACTH(4-10) fragment analogue |
| Structure | Synthetic heptapeptide | Synthetic short peptide |
| Emphasis in the literature | Anxiolytic, GABAergic | Neurotrophic, cognitive |
| Studied mechanisms | GABAergic signaling, BDNF, monoamine balance, enkephalin-degradation | BDNF and NGF expression, dopaminergic/serotonergic signaling |
| Research status | Early human, limited data | Early human, small number of studies |
| Sex-stratified human outcomes | None reported | None reported |
| Female-specific data | Unstudied across cycle, hormonal, pregnancy, menopause | Unstudied across cycle, hormonal, pregnancy, menopause |
Where the evidence actually stands
Both compounds sit at the early-human stage, and the emphasis on "early" and "limited" is doing real work. Selank's human data remains limited; most of Semax's human research comes from a small number of studies. Neither has an established therapeutic dose in most jurisdictions. So while the mechanistic stories differ in interesting ways, the strength of the human evidence behind them is similar, and modest.
Early studies report dose ranges for both compounds, but neither has an established therapeutic dose in most jurisdictions, and any figures are research context only. This site does not publish personal dosing, protocols, or medical advice.
The gap they share
For all their differences in origin and pathway emphasis, the most striking thing Selank and Semax have in common is what neither has studied. For both, there is no menstrual-cycle interaction data, no hormonal-interaction data, no pregnancy or lactation safety data, and no data in perimenopausal or menopausal populations. Many studies included female subjects; none reported outcomes by sex. In this database's terms, the female evidence for each is unstudied, an honest state rather than a blank we would ever fill by extrapolation.
If you are comparing these two to choose between them, the more useful frame is that both are early-stage research materials with different mechanistic emphases and the same unanswered question about women. For the full per-compound record, see the Selank and Semax profiles, and for the broader context see the cognitive and brain-fog peptides overview.